Epirubicin
Clear Cell Sarcoma
Seattle Children's HospitalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Clear Cell Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate University of Florida | Phase 1/2 | CCC |
Hycamtin Salarius Pharmaceuticals, LLC | Phase 1 | CC |
Rapamycin Emory University | Phase 1 | CC |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 1 | CC |
SIMVASTATIN Emory University | Phase 1 | CC |
View all 13 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →